February 29, 2008 - Physicians began performing the first European implants of the COGNIS cardiac resynchronization therapy defibrillator (CRT-D) and the TELIGEN implantable cardioverter defibrillator (ICD) by Boston Scientific Corp. after both devices received CE Mark last month.
The COGNIS CRT-D and the TELIGEN ICD are small and thin high-energy devices, measuring 32.5 cc and 31.5 cc respectively, while less than 10 mm thick. They offer features based on significant engineering advances, including extended battery longevity, self-correcting software and improved programming technology. These devices are built on an entirely new technology platform and are the result of a multi-year research and development effort to provide physicians enhanced clinical options for their patients.
Forty implants have been performed in 14 hospitals in six countries.
This week’s implants represent the beginning of the market launch in Europe. The Company plans to build to a full launch in Europe and other international markets in the second quarter.
“The COGNIS CRT-D offers extended battery longevity and several new features that will help me better manage my heart failure patients,” said Poul-Erik Bloch-Thomsen, M.D., Gentofte Hospital, Hellerup, Denmark. “For example, the
SmartDelay feature recommends programmable device settings, which enable meto tailor individualized pacing therapies.”
The COGNIS CRT-D and the TELIGEN ICD are pending approval by the FDA and are not available for sale in the United States.
For more information: www.bostonscientific.com
February 12, 2024 
